Abstract
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have